Dr. John Cush RheumNow
1 year 7 months ago
Nailfold video-capillaroscopy (NVC) study of 76 dermatomyositis (DM) pts - 74% had anomalous NVC patterns (diminished density, abnl morphology). NVC abnl pts had more Raynaud's, and cluster 1 were more likely to develop ILD.https://t.co/AsZ9CU2TZU https://t.co/TP1TMqotqi
Dr. John Cush RheumNow
1 year 7 months ago
41 "Rhupus" pts were compared to 160 SLE and 709 RA pts. Rhupus pts have a younger onset age than RA (P=0.032), but older than SLE (P=0.008). ~20% initially presented w/ SLE Sxs. Rhupus commonly has ILD, hyperglobulinemia & Lab abnormalities (61%), but seldom renal or CNS dz… https://t.co/m7VL6HHdUN https://t.co/i3knGVQYvj
Dr. John Cush RheumNow
1 year 7 months ago
Metanalysis of 41 studies, & 5343 AAV pts showed 55% (2890) had infection; 36% w/ severe infxn. This included PJP, aspergillosis, candidiasis, HZ, CMV, etc. Pulmonary most common. Risk factors included older, ESRD, DM, smoking, Renal or lung involvement https://t.co/yHo5BNlbiL https://t.co/R2je32YYGy
Dr. John Cush RheumNow
1 year 7 months ago
Palliative Care in Rheumatology
Dr. Jiha Lee talks with Dr. Shannon Herndon about abstracts 0204 and 1064, presented at the 2024 ACR Convergence meeting in Washington, DC.
https://t.co/fqx8wGLTqI https://t.co/5mwJx3ZN6u
Dr. John Cush RheumNow
1 year 7 months ago
95 IBD pts had Magnetic resonance enterography (MRE). While 6/95 (6.3%) developed IBD-arthritis (mean 11 mos), finding Sacroiliitison MRE did not increase this risk. IBD arthritis risk was linked to arthralgia (OR 84) & extraintestinal manifestations (OR 7.4)… https://t.co/NGWGKn75jG https://t.co/IqY6XHWqqy
Dr. John Cush RheumNow
1 year 7 months ago
Biomarker Study of 171 synovial fluid samples (54 primary OA, 57 RA, 30 Crystal,30 septic arthritis) examined the cartilage oligomeric matrix protein (COMP) to IL-8 ratio and found it can differentiate primary OA and inflamm arthritis w/ sensitivity 87% and specificity 89%… https://t.co/UH77DFgAlJ https://t.co/MfXQcl0BhW
Dr. John Cush RheumNow
1 year 7 months ago
Best of 2024: Prescription Painkiller Misuse in Chronic Pain Patients
https://t.co/AyccRCuAHh https://t.co/RYuvDwHANo
Dr. John Cush RheumNow
1 year 7 months ago
Abuse of the Safety-Net 340B Drug Programs
Dr. Madelaine Feldman comments on the 340B Drug Pricing Program, a safety-net initiative designed to provide costly therapies to vulnerable populations. She argues that the program has deviated from its original intent, with certain… https://t.co/5rIQHsIeAS https://t.co/rXwQPctHDf
A matched cohort study from the Veterans Health Administration shows that rheumatoid arthritis patients have a >50% increased risk of lung cancer, and a 3-fold higher risk of lung cancer in RA-interstitial lung disease (ILD).
A UK cross-sectional EHR clinical practice analysis between 2004 and 2020 shows that analgesic prescribing in inflammatory arthritis patients has declined, but still remains substantial, including opioid prescribing. Data was drawn from the Clinical Practice Research Datalink Aurum to evaluate analgesic prescription annual prevalence in patients with RA, PsA and axSpA and found that analgesic prescribing declined over time but remained common.
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Dr. John Cush RheumNow
1 year 7 months ago
ICYMI: JAKi in inflammatory myositis?
#ACR24 will showcase nearly 3000 abstracts. With the expanding use of JAK inhibitors, there will be some interesting presentations for off label use. There have been some uncontrolled data that tofacitinib reduced inflammatory myositis… https://t.co/8XOYOsDsD4 https://t.co/MF0EGO0BJz
Dr. John Cush RheumNow
1 year 7 months ago
Tocilizumab Efficacy in Giant Cell Arteritis Phenotypes
A Spanish Collaborative Group study of Tocilizumab (TCZ) in Giant Cell Arteritis (GCA) demonstrated high efficacy regardless of the different vascular phenotypes treated.
https://t.co/nwCU3qW4PT https://t.co/uhvFDrW5Zz
